Biolidics Trims Loss in Q3 as Revenue Rises 7%

MT Newswires
2024-11-04

Biolidics (SGX:8YY) loss for the third quarter of the year stood at SG$420,000, down nearly 30% year over year from SG$596,000, a filing with the Singapore Exchange said on Friday.

Loss per share came in at SG$0.0006 from SG$0.0007 in the year-ago period.

The diagnostic solutions provider's revenue was up 7% year over year to SG$15,000 from SG$14,000, mainly due to a slight increase in revenue from sales of CTChip FR1 biochip.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10